


List of Investigators


M. Abernathy, F. Adawi, M. Aguilar, M. Aguirre, A. Ahmed, A. Albota, L. Alder, O. Alvarado, M. Antsiferov, M Arciszewska, A. Arias, F. Balcazar, E. Balli, G. Bantiwal, M. Baranyai, J. Bardos, M. Barrientos-Peres, G. Bedel, T. Beljic-Zivkovic, R. Berbano, A. Bester, S. Bhana, T. Biniszkiwicz, J. Bjekic, T. Blevins, G. Bonabi, W. Boyd, A. Briel, D. Bruera, O. Brusco, Jr, R. Canadas, N. Cardenas, L. Carmona-Furusho, A. Carr, M. Castro, K. Cerna, A. Chacra, J. Chandler, Y. Cherny, D. Cheta, C. Chrisman, J. Cohen, G. Collins, Z. Crncevic-Orlic, J. Cuadrado, A. Dande, V. Dautaraite, D. Davis, O. De Leon Soto, R. De Leon Mazariegos, J. Delgado, J. Dent III, T. Derczynski, J. Dicke, G. Dieuzeide, I. Dina, M. Dinato, A. Djukie, C. Dominguez, A. Doshi, J. Dow, M. Dudas, A. Dumitrescu, S. Dunmyer, P. Dunn, J. DzuPONOVA, J. Eberly, B. Evans, P. Farkas, J. Fears, J. Felicio, S. Fica, A. Forti, M. Fraenkel, R. Fuchs, M. Fulat, I. Fushtey, L. Futo, Z. Gaal, S. Galdamez, P. Gandhi, M. Gani, R. Gaona, R. Garcia, J.F. Garcia, R. Geiger, G. Ghise, D. Gibson, C. Gilfillan, J. Gillies, L. Glaser, J. Godoy, B. Goldstein, R. Gonzalez-Orellana, Y. Graham, A. Granados-Fuentes, J. Gross, A. Grunspan, A. Gupta, M. Hagan, A. Haider, M. Hassman, D. Head, M. Helman, B. Henry, S. Hermida, T. Herskovits, H. Hidalgo, Jr., R. Hingorani, R. Hippert, M. Hissa, J. Hoekstra, R. Hood, K. Hristozov, C. Huffman, S. Ifrim, M. Irfan, V. Ivanov, A. Jaffe, J. Jagadeesan, R. Jain, M. Jandric-Balen, J. Janick, D. Johnson, S. Jones, E. Juhasz, H. Jure, I. Karachentsev, C. Ketels, V. Khvorostinka, M. Kipnes, V. Kissova, D. Klonoff, M. Kmet, S. Kobic, R. Komatsu, A. Kosloff, J. Krebs, J. Kuleta, P. Kumar, J. Kundumadathil, N. Lalic, G. Ledesma, D. Lee, S. Leichter, D. Levinsky, L. Levinson, D. Lewis, R. Lorraine, G. Losoya, P. Mader, L. Maffei, H. Makan, L. Maletz, Z. Man, V. Marasaev, J. McGill, M. Mehta, C. Mello, C. Miller, O. Minuchin, V. Mohan, R. Moodley, Y. Mora, M. Morosanu, R. Moses, Y. Mostovoy, M. Muller, M. Munoz, K. Nagy, A. Navickas, J. Neto, R. Newman, E. Niclewicz, G. Nieuwoudt, A. Nolasco, R. Nunn, M. Oberoi, C. Oldfield, D. O'Neal, T. Oroszlan, J. Palencia-Prado, P. Pearlstein, T. Pertseva, M. Petkova, R. Petryka, H. Phatale, P. Phillips, S. Pitale, D. Popova, M. Protich L. Pullerits, D. Quinn, S. Radenkovic, L. Radzeviciene, N. Rassi, A. Reichman, M. Remesnyk, G. Reshedko, M. Riederman, M. Robinson, P. Romanczuk, V. Romanenko, M. Rosemore, J. Rosenstock, A. Rosenthal, C. Ruzsa, G. Ryckman, G. Saadah, R. Saavedra, M. Sachdev, L. Saenz, R. Sahay, K. Sall, J. Sanchez, L. Sanchez-Arriaga, J. Sawyer-Szewczyk, J. Schmidt, E. Schramm, S. Schwartz, B. Seaton, O. Serhiyenko, B. Sethi, J. Sgarbi, S. Shaikh, J. Shapiro, V. Shivane, J. Siekavizza-Giron, J. Silverblatt, A. Slavcheva, L. Smith, A. Sosale, G. Sposetti, V. Stalte, J. Stoker, I. Strautina, R. Struble, R. Strzinek, I. Stura, M. Szanto, A. Szocs, M. Takahashi, M. Teixeira, N. Temelkova, J. Thesing, M. Thomas, D. Thorne, L. Tomasova, A. Torres-Ramirez, T. Treimer, E. Turcios-Juarez, G. Uribe-Botero, F. Valeeva, E. Van Nieuwenhuizen, J. Vasil, D. Velickiene, A. Verbbovoy, L. Viitas, O. Voloshyma, N. Vorohobina, E. Vuchkova, J. Whalen, J. Wainstien, J. Waitman, J. Wall, P. Weissman, F. Whittier, Jr., L. Zabuliene, D. Zeitser, B. Zilaitiene, A. Zvaigzne

APPENDIX FIGURES

Supplementary Figure 1— Schematic of study design.



Supplementary Figure 2— Disposition of subjects. Hyperglycemic rescue and discontinued were mutually exclusive groups; those subjects rescued due to hyperglycemia were not counted as discontinued. One subject from the A12.5 + P30 group was lost to follow-up; it was not confirmed whether the subject had taken a dose of study medication.



Abbreviations: FAS = full analysis set; VW = voluntary withdrawal; AE = adverse event; MPV = major protocol violation; LFU = lost to follow-up; ID = investigator discretion

Supplementary Figure 3

A and B— Time-course for mean HbA_{1c} (Panel A) and mean FPG (Panel B) during 26-week treatment with alogliptin monotherapy (25 mg qd, open triangles, A25 alone), pioglitazone monotherapy (30 mg qd, open circles, P30 alone), combination therapy with alogliptin 12.5 mg qd and pioglitazone 30 mg qd (closed diamonds, A12.5+P30), or combination therapy with alogliptin 25 mg qd and pioglitazone 30 mg qd (closed triangles, A25+P30). Mean±SE, n for first time point is given in parentheses.

C and D— Between-group comparison of the least-squares mean change (LSMΔ) in HbA_{1c} (Panel C) and FPG (Panel D) from baseline to Week 26 with last observation carried forward (LOCF). Mean±SE. Closed bars, A25 alone; open bars, P30 alone; lightly shaded bars, A12.5+P30; darkly stippled bars A25+P30. **P*<0.001 for combinations vs P30 alone, †*P*<0.001 and §*P*<0.01 for comparison of A25+P30 vs A25 alone. ‡*P*<0.05 for combinations vs pioglitazone monotherapy.

